Data protection essentials

Data protection laws in both the UK and EEA (the EU plus Iceland, Norway, and Liechtenstein) are intended to ensure information about living individuals (within the definition of ‘personal data’) is used fairly and responsibly.

To help ensure that, both the UK and EEA data protection laws impose a large number of obligations on those ‘processing’ personal data (and on controllers of such processing) and grant rights to those whose personal data is processed (the ‘data subjects’). In summary, ‘processing’ includes doing almost anything with personal data, including storing, sharing, deleting or using it.

UK data protection law is largely derived from EEA data protection laws and is therefore generally based on similar principles, although there are some detailed differences.

This subtopic provides certain core resources commonly required by commercial lawyers when addressing UK and EEA data protection laws under:

•
the EU’s General Data Protection Regulation, Regulation (EU) 2016/679 (EU GDPR) regime, which applies under the

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

EMA updates clinical data publication guidance with mandatory anonymisation templates

The European Medicines Agency (EMA) has published Version 1.5 of its external guidance on the implementation of Policy 0070, which governs the publication of clinical data for medicinal products for human use. The updated guidance clarifies and consolidates procedures relating to the submission, anonymisation, and redaction of clinical reports submitted in centralised marketing authorisation procedures. It provides revised instructions for applicants and marketing authorisation holders (MAHs) on the preparation of redacted and anonymised clinical documents, including the use of mandatory templates for justification tables and anonymisation reports.

MHRA launches major clinical trials overhaul, real-world data consultation and Inclusion and Diversity Plan pilot

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced the most significant update to the UK’s clinical trials regulatory framework in over two decades, aligning with International Clinical Trials Day. The reforms aim to create a more efficient, inclusive, and adaptable environment for clinical research in the UK, placing participants at the centre of the process and expediting the approval and delivery of innovative treatments to patients and the NHS. These changes are part of a broader strategy to secure the UK’s global leadership in life sciences and clinical research.

NICE updates health technology evaluation manual with new inequality assessment methods

The National Institute for Health and Care Excellence (NICE) has published a modular update to its health technology evaluations manual, introducing new methodological requirements for assessing health inequalities. The update implements 'distributional cost-effectiveness analysis' approaches and provides updated guidance for pharmaceutical companies and assessment groups on producing evidence of health inequality impacts. The changes aim to enable NICE committees to evaluate health inequalities more systematically when making NHS technology recommendations. This represents the first implementation under NICE's 2024 modular updates framework.

EFPIA warns against proposed EU medicine supply obligations for all Member States

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has responded to proposed EU legislation that would require pharmaceutical companies to launch and continuously supply products in all Member States. EFPIA's analysis, based on data from 94 medicines approved between January 2021 and June 2024, argues that such mandatory launch requirements would not address underlying causes of market access delays, which their research indicates are primarily due to national regulatory processes.